natgillin/translations-raw huggingface dataset:
Your doctor will also check your blood pressure regularly as Leflunomide medac can cause an increase in blood pressure. 
Prav tako vam bo vaš zdravnik redno meril krvni tlak, saj ga zdravilo Leflunomid medac lahko zviša.
If you suspect that you are pregnant while taking Leflunomide medac or in the two years after you have stopped treatment, you must contact your doctor immediately for a pregnancy test. 
Če med jemanjem zdravila Leflunomid medac ali v dveh letih po koncu zdravljenja posumite, da ste zanosili, morate o tem nemudoma obvestiti svojega zdravnika in opraviti nosečnostni test.
After stopping treatment with leflunomide: 
Postopek izpiranja Po prenehanju zdravljenja z leflunomidom:
The efficacy of Leflunomide medac in the treatment of rheumatoid arthritis was demonstrated in 4 controlled trials (1 in phase II and 3 in phase III). 
Učinkovitost zdravila Leflunomid medac so pri zdravljenju revmatoidnega artritisa dokazali v 4 kontroliranih preskušanjih (1 v II.
• tendonitis (pain caused by inflammation in the membrane surrounding the tendons usually in the feet or hands), 
• tendonitis (bolečina, običajno v rokah in nogah, ki jo povzroči vnetje membrane, ki obdaja tetive),
Film-coating: lecithin (soybeans) poly(vinyl alcohol) talc titanium dioxide (E 171) xanthan gum 
Filmska obloga: lecitin (sojina zrna) polivinil alkohol smukec titanov dioksid (E 171) ksantan gumi
• Patients with significantly impaired bone marrow function or significant anaemia, leucopenia, neutropenia or thrombocytopenia due to causes other than rheumatoid or psoriatic arthritis. 
• Bolniki z občutno okvarjenim delovanjem kostnega mozga ali izrazito anemijo, levkopenijo, nevtropenijo ali trombocitopenijo, katerih vzrok ni revmatoidni artritis ali psoriatični artritis.
Leflunomide medac belongs to a group of medicines called anti-rheumatic medicines. 
Zdravilo Leflunomid medac spada v skupino zdravil, ki jih imenujemo antirevmatična zdravila.
What Leflunomide medac is and what it is used for 
Kaj je zdravilo Leflunomid medac in za kaj ga uporabljamo
Marketing Authorisation Holder medac 
Imetnik dovoljenja za promet medac
• if you have moderate to severe kidney problems, 
• če imate zmerne do hude težave z ledvicami,
Certain vaccinations should not be given while taking Leflunomide medac, and for a certain amount of time after stopping treatment. 
Določenih cepiv se med uporabo zdravila Leflunomid medac in določen čas po koncu tega zdravljenja ne sme uporabljati.
• a decrease in the levels of phosphate in the blood. 
• zmanjšanje koncentracije fosfata v krvi.
You will normally take Leflunomide medac over long periods of time. 
Običajno boste zdravilo Leflunomid medac jemali dolgo časa.
The results of a population pharmacokinetic analysis of these trials have demonstrated that paediatric patients with body weights ≤ 40 kg have a reduced systemic exposure (measured by Css) of A771726 relative to adult rheumatoid arthritis patients (see section 4.2). 
Rezultati populacijske farmakokinetične analize teh preskušanj so pokazali, da je pri pediatričnih bolnikih s telesno maso 40 kg sistemska izpostavljenost A771726 (merjena s Css) manjša kot pri odraslih bolnikih z revmatoidnim artritisom (glejte poglavje 4.2).
• duloxetine for depression, urinary incontinence or in kidney disease in diabetics 
• duloksetin za zdravljenje depresije, inkontinence urina ali bolezni ledvic pri sladkornih bolnikih,
In a study in which leflunomide was given concomitantly with a triphasic oral contraceptive pill containing 30 μg ethinyloestradiol to healthy female volunteers, there was no reduction in contraceptive activity of the pill, and A771726 pharmacokinetics were within predicted ranges. 
V študiji, v kateri so zdravim prostovoljkam dajali leflunomid sočasno s trifaznimi kontracepcijskimi tabletami, ki so vsebovale 30 µg etinilestradiola, se kontracepcijsko delovanje tablet ni zmanjšalo, farmakokinetika A771726 pa je bila v predvidenem območju.
Co-administration of teriflunomide with leflunomide is not recommended, as leflunomide is the parent compound of teriflunomide. 
Teriflunomida in leflunomida ni priporočljivo uporabljati hkrati, ker je leflunomid osnovna spojina teriflunomida.
• The other ingredients are lactose monohydrate, low-substituted hydroxypropyl cellulose, tartaric acid, sodium laurylsulfate and magnesium stearate in the tablet core as well as lecithin (soybeans), poly(vinyl alcohol), talc, titanium dioxide (E 171) and xanthan gum in the film-coating. 
• Pomožne snovi so: laktoza monohidrat, hidroksipropil celuloza (nizko substituirana), vinska kislina, natrijev lavrilsulfat in magnezijev stearat v jedru tablete ter lecitin (sojina zrna), polivinil alkohol, smukec, titanov dioksid (E 171) in ksantan gumi v filmski oblogi.
• an increase in the levels of fat in the blood (cholesterol and triglycerides), 
• zvečanje koncentracije maščob v krvi (holesterola in trigliceridov),
What you need to know before you take Leflunomide medac 
Kaj morate vedeti, preden boste vzeli zdravilo Leflunomid medac
• Hypersensitivity (especially previous Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme) to the active substance, to the principal active metabolite teriflunomide, peanut or soya or to any of the excipients listed in section 6.1. 
• Preobčutljivost (posebno s predhodnim Stevens-Johnsonovim sindromom, toksično epidermalno nekrolizo, multiformnim eritemom) na zdravilno učinkovino, osnovni aktivni presnovek teriflunomid, zemeljske oreščke ali sojo ali katerokoli pomožno snov, navedeno v poglavju 6.1.
• indomethacin, ketoprofen for pain or inflammation 
• indometacin, ketoprofen za bolečino ali vnetje,
Tablet core: lactose monohydrate low-substituted hydroxypropyl cellulose tartaric acid sodium laurylsulfate magnesium stearate 
Jedro tablete: laktoza monohidrat hidroksipropil celuloza (nizko substituirana) vinska kislina natrijev lavrilsulfat magnezijev stearat
Patients were 317 years of age with active polyarticular course JRA regardless of onset type and naive to methotrexate or leflunomide. 
Bolniki so bili stari od 3 do 17 let, imeli so aktiven JRA s poliartikularnim potekom, ne glede na način pojava, in še niso dobivali metotreksata ali leflunomida.
• an increase in the numbers of blood cells called eosinophiles (eosinophilia); mild decrease in the number of white blood cells (leucopenia); decrease in the number of all blood cells 
• zvečanje števila krvnih celic imenovanih eozinofilci (eozinofilija); blago zmanjšanje števila belih krvnih celic (levkopenija); zmanjšanje števila vseh krvnih celic (pancitopenija),
(pancytopenia), 
(trombocitopenija),
• severe sometimes life-threatening reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme). 
• hude, včasih življenje ogrožujoče reakcije (Stevens-Johnsonov sindrom, toksična epidermalna nekroliza, multiformni eritem).
• cough or breathing problems as these may indicate problems of the lung (interstitial lung disease or pulmonary hypertension), 
• kašelj ali oteženo dihanje, ki lahko nakazujeta težave s pljuči (intersticijska bolezen pljuč ali pljuèna hipertenzija),
• other medicines for rheumatoid arthritis such as antimalarials (e.g. chloroquine and hydroxychloroquine), intramuscular or oral gold, D-penicillamine, azathioprine and other immunosuppressive drugs (e.g. methotrexate) as these combinations are not advisable, 
• druga zdravila za zdravljenje revmatoidnega artritisa, kot so antimalariki (npr. klorokin in hidroksiklorokin), intramuskularno ali peroralno dano zlato, D-penicilamin, azatioprin in druga imunosupresivna zdravila (npr. metotreksat), saj te kombinacije niso priporočljive,
As soon as skin and/or mucosal reactions are observed which raise the suspicion of such severe reactions, Leflunomide medac and any other possibly associated treatment must be discontinued, and a leflunomide washout procedure initiated immediately. 
Čim se na koži in/ali sluznici pojavijo reakcije, ki zbujajo sum na takšne hude reakcije, je treba prekiniti uporabo zdravila Leflunomid medac in drugih zdravil, ki bi jih lahko povzročila, in takoj začeti postopek izpiranja.
In a small (n = 30) study with co-administration of leflunomide (10 to 20 mg per day) with methotrexate (10 to 25 mg per week) a 2- to 3-fold elevation in liver enzymes was seen on 5 of 30 patients. 
V majhni (n = 30) študiji sočasne uporabe leflunomida (10 do 20 mg na dan) in metotreksata (10 do 25 mg na teden) se je pri 5 od 30 bolnikov pojavilo 2- do 3-kratno zvišanje jetrnih encimov.
• warfarin and other oral medicines used to thin the blood, as monitoring is necessary to reduce the risk of side effects of this medicine 
• varfarin in druga peroralna zdravila, ki se uporabljajo za redčenje krvi, ker so potrebne kontrole,
At a dose level of 20 mg/day, average plasma concentration of A771726 at steady state is approximately 35 μg/ml. 
Pri odmerku 20 mg/dan je bila povprečna plazemska koncentracija A771726 v stanju dinamičnega ravnotežja približno 35 µg/ml.
Absorption Excretion data from the 
Podatki o ekskreciji iz študije
• an increase of certain enzymes in the blood (lactate dehydrogenase). 
• zvišanje določenih encimov v krvi (laktat-dehidrogenaza).
Therefore, when co-administered with substrates of OAT3, such as cefaclor, benzylpenicillin, ciprofloxacin, indomethacin, ketoprofen, furosemide, cimetidine, methotrexate, zidovudine, caution is recommended. 
Zato je med sočasno uporabo substratov OAT3, kakršni so cefaklor, benzilpenicilin, ciprofloksacin, indometacin, ketoprofen, furosemid, cimetidin, metotreksat ali zidovudin, priporočljiva previdnost.
Leflunomide 20 mg/day was significantly superior to placebo in reducing the symptoms of arthritis in patients with psoriatic arthritis: the PsARC (Psoriatic Arthritis treatment Response Criteria) responders were 59 % in the leflunomide group and 29.7 % in the placebo group by 6 months (p< 0.0001). 
Leflunomid v odmerku 20 mg/dan je simptome artritisa pri bolnikih s psoriatičnim artritisom zmanjšal značilno bolj kot placebo: bolnikov, ki so se odzvali po merilih PsARC (Psoriatic Arthritis treatment Response Criteria; merila odziva na zdravljenje psoriatičnega artritisa), je bilo do 6. meseca med prejemniki leflunomida 59 % in med prejemniki placeba 29,7 % (p < 0,0001).
• problems in the nerves of the arms or legs (peripheral neuropathy). 
• težave z živci rok ali nog (periferna nevropatija).
Most patients improved after discontinuation of Leflunomide medac. 
Večini bolnikov se je po prenehanju jemanja zdravila Leflunomid medac stanje izboljšalo.
• daunorubicin, doxorubicin, paclitaxel, or topotecan for cancer 
• daunorubicin, doksorubicin, paklitaksel, ali topotekan za zdravljenje raka,
In vitro inhibition studies in human liver microsomes suggest that cytochrome P450 (CYP) 1A2, 2C19 and 3A4 are involved in leflunomide metabolism. 
Študije zaviranja in vitro z mikrosomi humanih jeter kažejo, da so v presnovo leflunomida vključeni citokromi P450 (CYP) 1A2, 2C19 in 3A4.
• inflammation of the small vessels (vasculitis, including cutaneous necrotizing vasculitis), 
• vnetje majhnih žil (vaskulitis, vključno s kožnim nekrotizirajočim vaskulitisom),
• a marked decrease of some white blood cells (agranulocytosis), 
• izrazito zmanjšanje nekaterih belih krvnih celic (agranulocitoza),
• The identified risk of synergistic hepato- or haematotoxicity associated with combination therapy with another Disease-Modifying Antirheumatic Drug (e.g. methotrexate). 
• O ugotovljenem tveganju za sinergistično hepato ali hemato toksičnost v povezavi s kombinirano terapijo z drugimi imunomodulirajočimi protirevmatičnimi zdravili (DMARDdisease-modifying antirheumatic drug) zdravili (na primer metotreksat).
After 12 months with active treatment, the ACR response rates in leflunomide patients were 52.3 % (studies MN301/303), 50.5 % (study MN302) and 49.4 % (study US301), compared to 53.8 % (studies MN301/303) in sulphasalazine patients, 64.8 % (study MN302), and 43.9 % (study US301) in methotrexate patients. 
ACR pri bolnikih na leflunomidu 52,3 % (študiji MN301/303), 50,5 % (študija MN302) in 49,4 % (študija US301) v primerjavi s 53,8 % (študiji MN301/303) pri bolnikih na sulfasalazinu ter 64,8 % (študija MN302) oz. 43,9 % (študija US301) pri bolnikih na metotreksatu.
Symptoms of psoriatic arthritis include inflammation of joints, swelling, difficulty in moving, pain, and patches of red, scaly skin (skin lesions). 
Simptomi aktivnega psoriatičnega artritisa vključujejo vnetje sklepov, zatekanje, težko premikanje, bolečine in rdeče, luskaste površine na koži (lezije kože).
Leflunomide medac is contraindicated in pregnancy (see section 4.3). 
Zdravilo Leflunomid medac je kontraindicirano med nosečnostjo (glejte poglavje 4.3).
• an increase of certain enzymes in the blood (creatine phosphokinase), 
• zvišanje določenih encimov v krvi (kreatin-fosfokinaza),
Tell your doctor if you plan to become pregnant after stopping treatment with Leflunomide medac, as you need to ensure that all traces of Leflunomide medac have left your body before trying to become pregnant. 
Povejte svojemu zdravniku, če nameravate po prenehanju zdravljenja z zdravilom Leflunomid medac zanositi, saj se morate, preden poskušate zanositi prepričati, da v telesu ni več ostankov zdravila Leflunomid medac.
The usual starting dosage of Leflunomide medac is 100 mg once daily for the first three days. 
Običajni začetni odmerek zdravila Leflunomid medac je ena 100-mg tableta enkrat na dan prve tri dni.
Leflunomide medac is contraindicated in patients with severe hypoproteinaemia or impairment of liver function (see section 4.3). 
Zdravilo Leflunomid medac je kontraindicirano pri bolnikih s hudo hipoproteinemijo ali okvarjenim delovanjem jeter (glejte poglavje 4.3).
• a slight decrease in the number of white blood cells (leucopenia), 
• rahlo zmanjšanje števila belih krvnih celic (levkopenija),
Human pharmacology Leflunomide is a disease-modifying anti-rheumatic agent with antiproliferative properties. 
Farmakologija pri ljudeh Leflunomid je imunomodulirajoče antirevmatično zdravilo z antiproliferacijskimi lastnostmi.
If a patient taking Leflunomide medac develops a peripheral neuropathy, consider discontinuing Leflunomide medac therapy and performing the drug elimination procedure (see section 4.4). 
Če bolnik med jemanjem zdravila Leflunomid medac razvije periferno nevopatijo, je potrebno razmisliti o ukinitvi terapije z zdravilom Leflunomid medac in o izvajanju postopka za eliminacijo zdravila (glejte poglavje 4.4).
• repaglinide, pioglitazone, nateglinide, or rosiglitazone for diabetes 
• repaglinid, pioglitazon, nateglinid, ali rosiglitazon za zdravljenej sladkorne bolezni,
Adverse events consistent with the safety profile for leflunomide were: abdominal pain, nausea, diarrhoea, elevated liver enzymes, anaemia, leucopenia, pruritus and rash. 
Neželeni učinki, skladni z varnostnim profilom leflunomida, so bili: bolečine v trebuhu, navzea, driska, zvišani jetrni encimi, anemija, levkopenija, srbenje in izpuščaj.
• active rheumatoid arthritis as a "disease-modifying antirheumatic drug" (DMARD). 
• aktivnim revmatoidnim artritisom kot imunomodulirajoče antirevmatično zdravilo (DMARD
Leflunomide medac can make you feel dizzy which may impair your ability to concentrate and react. 
Vpliv na sposobnost upravljanja vozil in strojev Zdravilo Leflunomid medac lahko povzroči omotičnost, kar lahko prizadene sposobnost za koncentracijo in reagiranje.
• eczema, dry skin, rash, itching, 
• ekcem, suha koža, izpuščaj, srbenje,
If you are already taking a non-steroidal anti-inflammatory drug (NSAID) and/or corticosteroids, you may continue to take them after starting Leflunomide medac. 
Če že jemljete nesteroidna protivnetna zdravila (NSAID) ali kortikosteroide ali oboje, lahko z njimi nadaljujete tudi po začetku uporabe zdravila Leflunomid medac.
• any symptoms of an infection such as fever, sore throat or cough, as this medicine may increase the chance of a severe infection which may be life-threatening, 
• simptome, kot so vročina, vneto grlo ali kašelj, ki nakazujejo okužbo, saj to zdravilo lahko poveča možnost nastanka hudih vnetij, ki so lahko usodna,
Do not use this medicine after the expiry date which is stated on the outer carton and on the bottle after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na ovojnini in plastenki poleg oznake EXP. Datum izteka roka uporabnosti se nanaša na zadnji dan navedenega meseca.
• tiredness, abdominal pain, or jaundice (yellow discolouration of the eyes or skin), as these may indicate serious conditions such as liver failure, which may be fatal, 
• utrujenost, bolečine v trebuhu ali zlatenico (porumenelost oči ali kože), ki so lahko znak resnih bolezni, kot je bolezen jeter, ki je lahko smrtna,
This metabolite is responsible for essentially all the in-vivo activity of Leflunomide medac. 
Ta je odgovoren za praktično vso aktivnost zdravila Leflunomid medac in vivo.
C-leflunomide in three healthy volunteers, no unchanged leflunomide was detected in plasma, urine or faeces. 
3 zdravih prostovoljcih v plazmi, urinu ali blatu niso našli nespremenjenega leflunomida.
• if you develop a skin rash or ulcers in your mouth, as these may indicate severe, sometimes life-threatening reactions (e.g. Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS]), see section 2. 
• če se vam razvijejo kožni izpuščaji ali razjede v ustih, je to lahko znak smrtno nevarnih reakcij (npr. Stevens-Johnsonov sindrom, toksična epidermalna nekroliza, multiformni eritem, neželena reakcija z eozinofilijo in sistemskimi simptomi [sindrom DRESS]), glejte poglavje 2.
• inflammation of the mouth or mouth ulcers, 
• vnetje v ustih ali razjede v ustih,
• sulfasalazine for inflammatory bowel disease or rheumatoid arthritis 
• sulfasalazin za zdravljenej vnetne bolezeni črevesa ali revmatoidnega artritisa,
How to store Leflunomide medac Contents of the pack and other information 
Shranjevanje zdravila Leflunomid medac Vsebina pakiranja in dodatne informacije
A randomised study assessed the clinical efficacy response rate in DMARD-naïve patients (n = 121) with early RA, who received either 20 mg or 100 mg of leflunomide with matching placebo in two parallel groups during the initial three day double blind period. 
Randomizirana študija je ocenila delež odzivnosti pri bolnikih (n = 121), ki še niso bili zdravljeni z imunomodulirajočimi protirevmatičnimi zdravili, so imeli zgoden RA in so med uvodnim tridnevnim dvojno slepim obdobjem prejemali bodisi 20 mg bodisi 100 mg leflunomida v dveh vzporednih skupinah.
• Colestyramine 8 g is administered 3 times daily for a period of 11 days. 
• Se v obdobju 11 dni uporabi po 8 g holestiramina 3-krat na dan.
In case of severe haematological reactions, including pancytopenia, Leflunomide medac and any concomitant myelosuppressive treatment must be discontinued and a leflunomide washout procedure initiated. 
V primeru hudih hematoloških reakcij, vključno s pancitopenijo, je treba prekiniti uporabo zdravila Leflunomid medac in morebitnih drugih mielosupresivnih zdravil ter začeti postopek izpiranja leflunomida.
Warnings and precautions Talk to your doctor, pharmacist or nurse before taking Leflunomide medac 
Opozorila in previdnostni ukrepi Pred začetkom uporabe zdravila Leflunomid medac se posvetujte s svojim zdravnikom, s farmacevtom ali z medicinsko sestro:
Do not take Leflunomide medac when you are breast-feeding, as leflunomide passes into the breast milk. 
Ne jemljite zdravila Leflunomid medac, če dojite, saj leflunomid lahko prehaja v mleko.
• inflammation of the lung (interstitial lung disease), 
• vnetje pljuč (intersticijska bolezen pljuč),
Interstitial lung disease, as well as rare cases of pulmonary hypertension have been reported during treatment with leflunomide (see section 4.8). 
Med zdravljenjem z leflunomidom je bila opisana intersticijska bolezen pljuč, pa tudi o redkih primerih pljučne hipertenzije (glejte poglavje 4.8).
• taste disturbances, 
• motnje okusa,
In the phase III trials, the ACR response rates for leflunomide 20 mg/day vs. placebo were 54.6 % vs. 28.6 % (study MN301), and 49.4 % vs. 26.3 % (study US301). 
V preskušanjih III. faze je bil delež odziva po ACR na leflunomid 20 mg/dan v primerjavi s placebom 54,6 % proti 28,6 % (študija MN301) in 49,4 % proti 26,3 % (študija US301).
UNIQUE IDENTIFIER - 2D BARCODE <2D barcode carrying the unique identifier included.> UNIQUE IDENTIFIER - HUMAN READABLE DATA 
EDINSTVENA OZNAKA - DVODIMENZIONALNA ČRTNA KODA <Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.>
• Alternatively, 50 g of activated powdered charcoal is administered 4 times daily for a period of 11 days. 
• Druga možnost je, da se v obdobju 11 dni uporabi po 50 g aktivnega oglja v prahu 4-krat na dan.
Very rare cases of Stevens-Johnson syndrome or toxic epidermal necrolysis and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have been reported in patients treated with leflunomide. 
Zelo redko so pri bolnikih, zdravljenih z leflunomidom, opisani Stevens-Johnsonov sindrom ali toksična epidermalna nekroliza in neželene reakcije z eozinofilijo in sistemskimi simptomi (sindrom DRESS - Drug Reaction with Eosinophilia and Systemic Symptoms).
Other medicines and Leflunomide medac 
Druga zdravila in zdravilo Leflunomid medac
The most frequently reported adverse effects with leflunomide are: mild increase in blood pressure, leucopenia, paraesthesia, headache, dizziness, diarrhoea, nausea, vomiting, oral mucosal disorders (e.g. aphthous stomatitis, mouth ulceration), abdominal pain, increased hair loss, eczema, rash (including maculo-papular rash), pruritus, dry skin, tenosynovitis, CPK increased, anorexia, weight loss (usually insignificant), asthenia, mild allergic reactions and elevation of liver parameters (transaminases [especially ALT], less often gamma-GT, alkaline phosphatise, bilirubin). 
Najpogostejši neželeni učinki, o katerih poročajo in so povezani z leflunomidom, so: blago zvišanje krvnega tlaka, levkopenija, parestezija, glavobol, omotica, driska, navzea, bruhanje, bolezni ustne sluznice (npr. aftozni stomatitis, razjede v ustih), bolečine v trebuhu, zvečano izpadanje las, ekcem, izpuščaji (vključno makulopapularni izpuščaji), pruritus, suha koža, tendosinovitis, zvišan CPK,
• a decrease in the number of red blood cells (anaemia) and a decrease in the number of blood platelets (thrombocytopenia), 
• zmanjšanje števila rdečih krvnih celic (anemija) in zmanjšanje števila krvnih ploščic
Other side effects such as kidney failure, a decrease in the levels of uric acid in your blood, pulmonary hypertension, male infertility (which is reversible once treatment with this medicine is stopped), cutaneous lupus (characterized by rash/erythema on skin areas that are exposed to light), psoriasis (new or worsening) and DRESS may also occur with an unknown frequency. 
Z neznano pogostnostjo se lahko pojavijo neželeni učinki, kot je ledvična odpoved, zmanjšana koncentracija sečne kisline v krvi, pljučna hipertenzija, neplodnost pri moških (izgine po prenehanju uporabe tega zdravila), kožni lupus (značilen izpuščaj/eritem na predelih kože, ki so izpostavljeni svetlobi), luskavica (ki se pojavi na novo ali poslabšanje le te) in sindrom DRESS.
leucopenia (leucocytes > 2 G/l) 
9/l) levkopenija (levkociti > 2 x 10
Repeated doses of A771726 decreased mean Cmax and AUC of caffeine (CYP1A2 substrate) by 18 % and 55 %, respectively, suggesting that A771726 may be a weak inducer of CYP1A2 in vivo. 
Ponavljajoči se odmerki A771726 so zmanjšali povprečno Cmax kofeina (ki je substrat CYP1A2) za 18 % in njegovo povprečno AUC za 55 %; to kaže, da A771726 in vivo morda šibko inducira CYP1A2.
The phase II trial, study YU203, randomised 402 subjects with active rheumatoid arthritis to placebo (n = 102), leflunomide 5 mg (n = 95), 10 mg (n = 101) or 25 mg/day (n = 104). 
faze, raziskave YU203, so 402 preiskovanca z aktivnim revmatoidnim artritisom randomizirano razvrstili na placebo (n = 102), leflunomid 5 mg (n = 95), 10 mg (n = 101) ali 25 mg/dan (n = 104).
• increased hair loss, 
• zvečano izpadanje las,